Differences in N-glycan Structures Found on Recombinant IgA1 and IgA2 Produced in Murine Myeloma and CHO Cell Lines

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2010 May 1

PMID 20431350

Citations 17

Authors

Esther M Yoo

Li J Yu

Letitia A Wims

David Goldberg

Sherie L Morrison

Affiliations

Soon will be listed here.

Abstract

The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic protection at mucosal surfaces. The choice of expression system for production of recombinant antibodies is crucial because they are glycoproteins containing at least one N-linked carbohydrate. These glycans have been shown to contribute to the stability, pharmacokinetics and biologic function of antibodies. We have produced recombinant human IgA1 and all three allotypes of IgA2 in murine myeloma and CHO cell lines to systematically characterize and compare the N-linked glycans. Recombinant IgAs produced in murine myelomas differ significantly from IgA found in humans in that they contain the highly immunogenic Galalpha(1,3)Gal epitope and N-glycolylneuraminic acid residues, indicating that murine myeloma is not the optimal expression system for the production of human IgA. In contrast, IgAs produced in CHO cells contained glycans that were more similar to those found on human IgA. Expression of IgA1 and IgA2 in Lec2 and Lec8 cell lines that are defective in glycan processing resulted in a less complex pool of N-glycans. In addition, the level of sialylation of rIgAs produced in murine and CHO cells was significantly lower than that previously reported for serum IgA1. These data underscore the importance of choosing the appropriate cell line for the production of glycoproteins with therapeutic potential.

Citing Articles

Effects of -glycans on the structure of human IgA2.

Ruocco V, Grunwald-Gruber C, Rad B, Tscheliessnig R, Hammel M, Strasser R Front Mol Biosci. 2024; 11:1390659.

PMID: 38645274 PMC: 11026580. DOI: 10.3389/fmolb.2024.1390659.

Considerations for Glycoprotein Production.

Clarke E Methods Mol Biol. 2024; 2762:329-351.

PMID: 38315375 DOI: 10.1007/978-1-0716-3666-4_20.

Advances in IgA glycosylation and its correlation with diseases.

Ding L, Chen X, Cheng H, Zhang T, Li Z Front Chem. 2022; 10:974854.

PMID: 36238099 PMC: 9552352. DOI: 10.3389/fchem.2022.974854.

3D Structures of IgA, IgM, and Components.

Pan S, Manabe N, Yamaguchi Y Int J Mol Sci. 2021; 22(23).

PMID: 34884580 PMC: 8657937. DOI: 10.3390/ijms222312776.

Secretory IgA N-glycans contribute to the protection against E. coli O55 infection of germ-free piglets.

Raskova Kafkova L, Brokesova D, Krupka M, Stehlikova Z, Dvorak J, Coufal S Mucosal Immunol. 2020; 14(2):511-522.

PMID: 32973324 PMC: 7946640. DOI: 10.1038/s41385-020-00345-8.

References

Tao M, Morrison S . Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989; 143(8):2595-601. View

Torano A, TSUZUKIDA Y, Liu Y, Putnam F . Location and structural significance of the oligosaccharides in human Ig-A1 and IgA2 immunoglobulins. Proc Natl Acad Sci U S A. 1977; 74(6):2301-5. PMC: 432158. DOI: 10.1073/pnas.74.6.2301. View

Vidarsson G, van der Pol W, van den Elsen J, Vile H, Jansen M, Duijs J . Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol. 2001; 166(10):6250-6. DOI: 10.4049/jimmunol.166.10.6250. View

Ma J, Hikmat B, Wycoff K, Vine N, Chargelegue D, Yu L . Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med. 1998; 4(5):601-6. DOI: 10.1038/nm0598-601. View

Galili U . Abnormal expression of alpha-galactosyl epitopes in man. A trigger for autoimmune processes?. Lancet. 1989; 2(8659):358-61. DOI: 10.1016/s0140-6736(89)90539-4. View

Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A . Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A. 2003; 100(21):12045-50. PMC: 218710. DOI: 10.1073/pnas.2131556100. View

Shibuya A, Sakamoto N, Shimizu Y, Shibuya K, Osawa M, Hiroyama T . Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol. 2001; 1(5):441-6. DOI: 10.1038/80886. View

Goldberg D, Sutton-Smith M, Paulson J, Dell A . Automatic annotation of matrix-assisted laser desorption/ionization N-glycan spectra. Proteomics. 2005; 5(4):865-75. DOI: 10.1002/pmic.200401071. View

Baenziger J, Kornfeld S . Structure of the carbohydrate units of IgA1 immunoglobulin. I. Composition, glycopeptide isolation, and structure of the asparagine-linked oligosaccharide units. J Biol Chem. 1974; 249(22):7260-9. View

10.

Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q . Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and.... Anal Biochem. 2007; 364(1):8-18. DOI: 10.1016/j.ab.2007.01.023. View

11.

Oelmann S, Stanley P, Gerardy-Schahn R . Point mutations identified in Lec8 Chinese hamster ovary glycosylation mutants that inactivate both the UDP-galactose and CMP-sialic acid transporters. J Biol Chem. 2001; 276(28):26291-300. DOI: 10.1074/jbc.M011124200. View

12.

Otten M, Rudolph E, Dechant M, Tuk C, Reijmers R, Beelen R . Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol. 2005; 174(9):5472-80. DOI: 10.4049/jimmunol.174.9.5472. View

13.

Taylor A, Wall R . Selective removal of alpha heavy-chain glycosylation sites causes immunoglobulin A degradation and reduced secretion. Mol Cell Biol. 1988; 8(10):4197-203. PMC: 365490. DOI: 10.1128/mcb.8.10.4197-4203.1988. View

14.

Peipp M, Lammerts van Bueren J, Schneider-Merck T, Bleeker W, Dechant M, Beyer T . Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008; 112(6):2390-9. DOI: 10.1182/blood-2008-03-144600. View

15.

Iwanami N, Iwase H, Takahashi N, Kato K, Itoh A, Takatani T . Similarities between N-glycan glycoform of tonsillar IgA1 and that of aberrant IgA1 abundant in IgA nephropathy patient serum. J Nephrol. 2008; 21(1):118-26. View

16.

Stockmeyer B, Dechant M, van Egmond M, Tutt A, Sundarapandiyan K, Graziano R . Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol. 2000; 165(10):5954-61. DOI: 10.4049/jimmunol.165.10.5954. View

17.

Tomana M, Novak J, Julian B, Matousovic K, Konecny K, Mestecky J . Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999; 104(1):73-81. PMC: 408399. DOI: 10.1172/JCI5535. View

18.

Atkin J, Pleass R, Owens R, Woof J . Mutagenesis of the human IgA1 heavy chain tailpiece that prevents dimer assembly. J Immunol. 1996; 157(1):156-9. View

19.

Phalipon A, Cardona A, Kraehenbuhl J, Edelman L, Sansonetti P, Corthesy B . Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity. 2002; 17(1):107-15. DOI: 10.1016/s1074-7613(02)00341-2. View

20.

Chintalacharuvu S, Nagy N, Sigmund N, Nedrud J, Amm M, Emancipator S . T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation. Clin Exp Immunol. 2001; 126(2):326-33. PMC: 1906199. DOI: 10.1046/j.1365-2249.2001.01678.x. View